Aspects of Peptidomimetics - Peptide and Protein Design for Biopharmaceutical Applications - page 122

Potent inhibitors of the hepatitis C virus NS3 protease: Design and synthesis of
macrocyclic substrate-based beta-strand mimics, J.Org.Chem ., 69, 6185-6201
(2004).
[260] A. B. Smith III, M. C. Guzman, P. A. Sprengeler, T. P. Keenan, R. C. Holcomb,
J. L. Wood, P. J. Carroll and R. Hirschmann, De novo design, synthesis and X-ray
crystal structures of pyrrolinone-based b-strand peptidomimetics, J.Am.Chem.Soc .,
116, 9947-9962 (1994).
[261] A. B. Smith, R. Hirschmann, A. Pasternak, R. Akaishi, M. C. Guzman, D. R. Jones,
T. P. Keenan, P. A. Sprengeler, P. L. Darke, E. A. Emini, M. K. Holloway and
W. A. Schleif, Design and synthesis of peptidomimetic inhibitors of HIV-1 protease
and renin - Evidence for improved transport, J.Med.Chem ., 37, 215-218 (1994).
[262] A. B. Smith, T. Nittoli, P. A. Sprengeler, J. J. W. Duan, R. Q. Liu and
R. F. Hirschmann, Design, synthesis, and evaluation of a pyrrolinone-based matrix
metalloprotease inhibitor, Org.Lett ., 2, 3809-3812 (2000).
[263] K. H. Lee, G. L. Olson, D. R. Bolin, A. B. Benowitz, P. A. Sprengeler, A. B. Smith,
R. F. Hirschmann and D. C. Wiley, The crystal structure of a pyrrolinone-peptide
hybrid ligand bound to the human class II MHC protein HLA-DR1,

J.Am.Chem.Soc ., 122, 8370-8375 (2000).
[264] A. B. Smith, A. K. Charnley, E. F. Mesaros, O. Kikuchi, W. Y. Wang, A. Benowitz,
C. L. Chu, J. J. Feng, K. H. Chen, A. Lin, F. C. Cheng, L. Taylor and R. Hirschmann,
Design,

synthesis, and binding affinities of pyrrolinone-based somatostatin

mimetics, Org.Lett ., 7, 399-402 (2005).
[265] S. T. Philips, M. Rezac, U. Abel, M. Kossenjans and P. A. Bartlett, '@-tides':
The 1,2-dihydro-3(6 H )-pyridinone unit as a b-strand mimic, J.Am.Chem.Soc .,
124, 58-59 (2002).
[266] S. T. Phillips, L. K. Blasdel and P. A. Bartlett, @-tides as reporters for molecular
associations, J.Am.Chem.Soc ., 127, 4193-4198 (2005).
[267] M. C. Hammond, B. Z. Harris, W. A. Lim and P. A. Bartlett, beta strand peptido-
mimetics as potent PDZ domain ligands, Chem.Biol ., 13, 1247-1251 (2006).
[268] M. C. Hammond and P. A. Bartlett, Synthesis of amino acid-derived cyclic acyl
amidines for use in beta-strand peptidomimetics, J.Org.Chem ., 72, 3104-3107
(2007).
[269] D. Blomberg, K. Brickmann and J. Kihlberg, Synthesis of a beta-strand mimetic
based on a pyridine scaffold, Tetrahedron , 62, 10937-10944 (2006).
[270] Y. M. Qian, M. A. Blaskovich, M. Saleem, C. M. Seong, S. P. Wathen, A. D.
Hamilton and S. M. Sebti, Design and structural requirements of potent peptido-
mimetic inhibitors of P21(Ras) farnesyltransferase, J.Biol.Chem ., 269, 12410-
12413 (1994).
[271] Y. M. Qian, A. Vogt, S. M. Sebti and A. D. Hamilton, Design and synthesis of non-
peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors, J.Med.Chem .,
39, 217-223 (1996).
[272] G. Semple, D. M. Ashworth, G. R. Baker, A. R. Batt, A. J. Baxter, D. W. M. Benzies,
L. H. Elliot, D. M. Evans, R. J. Franklin, P. Hudson, P. D. Jenkins, G. R. Pitt,
D. P. Rooker, A. Sheppard, M. SZELKE, S. Yamamoto and Y. Isomura, Pyridone-
based peptidomimetic inhibitors of interleukin-1 beta-converting enzyme (ICE),
Bioorg.Med.Chem.Lett ., 7, 1337-1342 (1997).
[273] J. M. C. Golec, M. D. Mullican, M. A. Murcko, K. P. Wilson, D. P. Kay,
S. D. Jones, R. Murdoch, G. W. Bemis, S. A. Raybuck, Y. P. Luong and